Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Combination Immunotherapy Platform FORT LAUDERDALE, FL. and BEIJING, China, October 18, 2022 (BUSINESS WIRE) – Syncromune, Inc., a clinical...
